ArticleDrug design, development and therapy2026

Ivonescimab Plus Chemotherapy versus Bevacizumab Plus Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After EGFR-TKI Failure: A Two-Center Retrospective Real-World Propensity Score-Matched Study.

Jianxi Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.